DRW Securities’s Cadrenal Therapeutics CVKD Stock Holding History

DRW Securities’s Portfolio CVKD Stock Details CVKD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-25,152	Closed	-$171K	–	1382
2025 Q4	$171K	Buy	+25,152	New	+$284K	﹤0.01%	1003

Other funds holding CVKD

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

DWP

Destiny Wealth Partners Tavares, Florida $914M AUM 18.14% 1-Year Est. Return

Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return

Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return

DRW Securities's CVKD Position: Q1 2026 in Review

DRW Securities sold out of Cadrenal Therapeutics (CVKD) in Q1 2026, closing a stake of 25,152 shares — an estimated $171K sold.

DRW Securities first reported a position in CVKD in Q4 2025 and held it in 1 quarter. The position peaked at $171K in Q4 2025. 20 funds tracked by Wall St. Rank hold CVKD as of Q1 2026.

DRW Securities reported no remaining Cadrenal Therapeutics position as of Q1 2026 after selling out during the quarter.
DRW Securities sold 25,152 Cadrenal Therapeutics shares in Q1 2026, an estimated $171K.
DRW Securities first reported a position in Cadrenal Therapeutics in Q4 2025 and held it in 1 quarter.
DRW Securities's Cadrenal Therapeutics position peaked at $171K in Q4 2025.
20 funds tracked by Wall St. Rank held Cadrenal Therapeutics as of Q1 2026.

Based on DRW Securities's 13F filing for Q1 2026, filed 13 May 2026.